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The following on proton pump inhibitors and chemoprevention in Barrett’s esophagus includes commentaries on
normalization of esophageal refluxate; the effects of 5-HT4 agonists on EGF secretion and of lubripristone on chloride
channels agents; the role of Campylobacter toxin production; the deleterious effects of unconjugated bile acids; the
role of baclofen in nonacid reflux; the threshold for adequate esophageal acid exposure; the effects of proton pump
inhibitor (PPI) therapy on normalization of esophageal pH and on cell proliferation; the role of the phenotype
of cellular proliferation on the effects of PPI therapy; and the value of Symptom Index and Symptom Association
Probability in the evaluation of potential response to treatment.
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Concise summaries
• In vitro data in cultured cells suggest that acid
andbile exposure is important inBarrett’s car-
cinogenesis.Normalizationof esophageal acid
exposure—albeit not formally proven in RCT
studies—should be beneficial in preventing
metaplasia in gastroesophageal reflux disease
(GERD) patients and potentially diminish the
likelihood of neoplastic progression.
• Esophageal preepithelial mucosal defense
mechanisms in patients with BE are sig-
nificantly impaired, potentially predispos-
ing metaplastic epithelium to further injury,
chronic inflammation and progression to
esophageal adenocarcinoma.
doi: 10.1111/j.1749-6632.2011.06047.x
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• 5-HT4 receptor expression significantly in-
creases from the controls to GERD and to BE
patients. 5-HT4 could play a role, involving
both EGF and COX-2 pathways, determining
PGE2 secretion increase and, conse-
quently, proliferative activity increase, and
5-HT4 selective antagonists could be the
future of GERD therapy and BE chemopre-
vention.
• The impact of chloride channel stimulators
on secretion of protective factors in disease of
the esophageal mucosa, especially in patients
with Barrett’s esophagus (BE) with and with-
out low/high-grade dysplasia (LGD/HGD),
remains to be explored.
• Acid suppression therapy with proton pump
inhibitors (PPIs) may lead to the bacterial
overgrowth and increased reflux of toxic,
unconjugated bile acids. This may result
in increased cell DNA damage, mutations,
and consequently to BE and EAC develop-
ment. However, the current knowledge about
esophageal colonization with Campylobacter
species does not justify eradication with an-
tibiotics.
• Most groups currently define adequate acid
control in GERD patients as values below
normal thresholds for healthy controls, usu-
ally a total acid exposure time of less than
4.5–5.5%.
• In patients in whom ongoing symptoms are
related to nonacidic reflux events, the reduc-
tion of TLESR frequency GABAB-receptor ag-
onists is a potentially beneficial therapeutic
strategy. Baclofen is a reasonable therapeutic
add-on in patients under PPIs with persistent
symptoms due to nonacid reflux.
• The epithelium of patients with continuous
acid exposure is believed to only partially
benefit from PPI therapy, whereas the ep-
ithelium of patients with pulse acid expo-
sure, leading to more pronounced epithe-
lial changes, might have a greater potential
to be positively influenced/cured by PPI
therapy.
• For an antisecretory treatment aimed at
chemoprevention to be effective, higher PPI
dosing, confirmed by pH monitoring, is nec-
essary. PPIs suppress cellular proliferation in
BE with the gastric-predominant mucin phe-
notype, but not in that with the intestinal-
predominant mucin phenotype. This finding
may partly explain the ongoing controversy
effects of acid-suppressive therapy in Barrett’s
patients.
• Great caution is recommended when using
Symptom Sensitivity Index and SymptomAs-
sociation Probability results to predict a re-
sponse to PPIs in individual patients, espe-
cially in those without classic heartburn or
regurgitation.
• There is no significant association between
esophageal adenocarcinoma and the use of
antisecretory agents per se.
1. Should the esophageal refluxate be




Two retrospective studies have suggested that con-
trolling esophageal pH may decrease the chances
to develop dysplasia. In a VA study, El Serag et al.1
compared the development of dysplasia in patients
with BE treated with or without PPI or histamine
2-receptor antagonist (H2RA) over a 20-year time
period. They found that the cumulative incidence
of dysplasia was significantly lower among patients
who received PPI after BE diagnosis than in those
who received no therapy or H2RA. Furthermore,
among those on PPIs, a longer duration of use
was associated with less frequent occurrence of
dysplasia. In the second study,2 Hillman et al. ex-
amined whether PPI therapy influences the in-
cidence and progression of dysplasia in patients
with BE. They found that ongoing PPI ther-
apy appeared beneficial in the prevention of dys-
plasia and adenocarcinoma in patients with BE
and suggested that all patients with this condi-
tion, even those with no esophagitis or symptoms,
should be encouraged to continue long term PPI
therapy.
Hence, control of the esophageal acid (and bile)
exposure by mechanical and pharmacologic means
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Figure 1. Outline of two scenarios that relate acid control and
Barrett’s pathogenesis and natural history. Originally published
in Ref. 3.
seems quite important in the pathogenesis and nat-
ural history of BE. Figure 1 highlights two possible
scenarios:3
(i) Under the first scenario, acid control before the
development of BEmay either abort the forma-
tion of metaplasia or be associated with shorter
segment metaplasia.
(ii) Under the second scenario that occurs after the
formation of metaplasia, effective acid control
could lead to less dysplasia and cancer, a chemo-
prevention effect.
Several recent in vitro studies have explored the
role of the refluxate, such as acid and bile, in af-
fecting BE formation and inducing alterations in
the Barrett’s cells that would, in turn, favor ma-
lignant transformation, but, for brevity, only two
recent ones are highlighted herein.
Under the first scenario, Huo et al. hypothe-
sized that differences among individuals in molec-
ular pathways activated when esophageal squamous
epithelium is exposed to refluxunderlie thedevelop-
ment of Barrett’s metaplasia.4 They used esophageal
squamous cell lines from patients who had GERD
with BE and without BE to study the effects of acid
and bile salts on expression of the CDX2 gene. They
found that both acid and bile salts increased CDX2
messenger RNA (mRNA), protein, and promoter
activity in NES-B3T and NES-B10T cells, but not in
NES-G2T orNES-G4T cells. They also foundCDX2
mRNA in 7 of 10 esophageal squamous biopsy spec-
imens frompatientswithBE, but in only 1 of 10 such
specimens from patients who had GERD without
BE. Since acid and bile salts induce CDX2 mRNA
andprotein expression in esophageal squamous cells
from patients with BE, but not fromGERD patients
without BE, they speculated that these differences in
acid- and bile salt-induced activation of molecular
pathwaysmay underlie the development of Barrett’s
metaplasia.
Hong et al. examined whether acid increases
methylation of p16 gene promoter and whether
NADPH oxidase NOX5-S mediates acid-induced
p16 hypermethylation in a Barrett’s cell line BAR-T
and an EA cell lineOE33.5 Inactivation of the tumor
suppressor gene p16 may be important in the ma-
lignant transformation of BE. Hypermethylation of
p16 gene promoter is an important mechanism in-
activatingp16.They found thatNOX5-Swaspresent
in BAR-T and OE33 cells and that acid-induced in-
crease in H2O2 production and cell proliferation
was significantly reduced by knockdown of NOX5-
S (Fig. 2). Exogenous H2O2 remarkably increased
p16 promoter methylation and cell proliferation. In
addition, acid treatment significantly increased p16
promoter methylation and decreased p16 mRNA
level.KnockdownofNOX5-S significantly increased
p16mRNA, inhibited acid-induced downregulation
of p16mRNA, and blocked acid-induced increase in
p16 methylation and cell proliferation. Conversely,
overexpression of NOX5-S significantly decreased
p16 mRNA and increased p16 methylation and cell
proliferation. The authors postulated that acid re-
flux may activate NOX5-S and increase produc-
tion of reactive oxygen species, which, in turn, in-
creasep16promotermethylation, downregulatep16
Figure 2. Acid increases methylation levels of p16 gene
promoter in BAR-T cells and OE33 cells in vitro.
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expression, and increase cell proliferation, thereby
contributing to malignant progression.
In conclusion, recent in vitro data in cultured
cells suggest that acid (and bile) exposure is
important in Barrett’s carcinogenesis. Normaliza-
tion of esophageal acid exposure—albeit not for-
mally proven in RCT studies—should be benefi-
cial in preventing metaplasia in GERD patients and
potentially diminish the likelihood of neoplastic
progression of BE.
2. Are esophageal mucosal defense
mechanisms different in BE?
Richard W. McCallum and Jerzy Sarosiek
Jerzy.sarosiek@ttuhsc.edu
GERD is defined as the presence of chronic
symptoms, predominantly including heartburn/
regurgitation with or without mucosal damage pro-
duced by an abnormal reflux, i.e., retrograde flow
of gastric or mixed duodeno-gastric content into
the esophagus and/or mouth. Considering the fact
that gastroesophageal refluxate (GER) contains a
range of injurious agents, fromacid accompanied by
seven to eight pepsins and to bile acids mixed with
acid/pepsins and pancreatic enzymes, esophageal
mucosa has to have in place a plethora of protective
factors counteracting these aggressive components,
thus preventing injury to the squamous epithelium.
Among the esophageal preepithelial protective fac-
tors elaborated by salivary or esophageal submu-
cosal mucous glands, buffers and mucins are the
leaders, followed by epidermal growth factor (EGF)
and transforming growth factor- (TGF-), repre-
senting a vanguard of mucosal protection in health
and disease.6
The concept of the role of mucosal protection
in health and disease
If protective mechanisms are inadequate or over-
whelmed qualitatively or quantitatively by an exces-
sive injurious refluxate, mucosal injury and subse-
quent repair will take place, thus setting the stage
for acute/chronic inflammation.7,8 It is squamous
epithelial repair, in an environment of unabated
reflux and dropping pH within the mucosa, that
leads highly proliferating mucosal stem cells to re-
place injured cells, to turn on mucosal differentia-
tion into columnar epithelium, called BE, which is
better equipped to cope with the luminal content
of gastroduodenal injurious components.7 Within
24 h, the composition of GER varies profoundly,
from highly and predominantly acidic, especially
during the after midnight hours, to highly con-
taminated with duodeno-gastric reflux during, and
shortly after, ingestion of various meals at day time.
This continuous variation in the composition of
injurious components within GER sets the stage
for the final phenotype of Barrett’s mucosal cells
as incomplete intestinal metaplasia (the mixture of
gastric and intestinal cells with some even express-
ing goblet cell morphology) that is still a subject
of injury/repair, as this columnar epithelium ex-
hibits still inadequate mucosal protection.6–8 This is
why highly injurious and proinflammatory stimuli
maintain chronic inflammation resulting, in some
patients, in the development of complications such
as LGD, HGD, and ultimately esophageal adenocar-
cinoma (AdCa).6–8
Although pathophysiology of GERD/BE includes
pan-esophageal motility disorder, including defec-
tive lower esophageal sphincter (LES), excessive
transient LES relaxation (TLESR), and impaired
primary and/or secondary esophageal peristalsis
and clearance, it is the degree of imbalance be-
tween aggressive factors and protective mechanisms
that will define absence or presence its final out-
come, esophageal adenocarcinoma.6–8 Setting the
stage for potential development of BE, patients with
reflux esophagitis have significant impairment in
esophageal mucin secretion, as well as esophageal
and salivary EGF, which persist even after healing
of erosive changes, indicating that this preexisting
condition facilitates the development ofmucosal in-
jury.6 Furthermore, esophageal EGF secretion also
remains impaired in patients with BE.9
Although therapy with PPIs improves the equi-
librium between aggressive factors and protec-
tive mechanisms by diminishing acidity of GER,
some PPIs, such as rabeprazole, may also increase
esophageal secretion of protective mucin after heal-
ing of erosive mucosal changes.10 Administration of
the serotonin receptor (5-HT4) agonist tegaserod,
and potentially other newer agents free of cardiac
side effects, results in significant increase in sali-
vary bicarbonate and nonbicarbonate buffers, EGF,
and TGF-, as well as esophageal EGF,6 promot-
ing further potential restoration of equilibrium.
This enhancement of equilibrium can be also pro-
moted further by mastication or chewing sugarless
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Figure 3. The relationship between disequilibrium between aggressive factors and protective mechanisms in the development of
L/HGD and esophageal adenocarcinoma in patients with BE.
chewing gum, which leads to a two- to four-
fold increase in salivary buffers, mucin, EGF, and
TGF-.8 Obviously, administration of GABAB re-
ceptor agonists (baclofen and the newest agents
tested in clinical trials) help to prevent GER through
inhibition of TLES relaxation.7 Perhaps in some pa-
tients with BE who still exhibit significant GER in
spite of BID doses of PPIs, addition of sugarless
chewing gum- and/or GABAB receptor antagonists
or 5-HT4 receptor agonist could lead to restoration
of equilibrium, thus diminishing profoundly subse-
quent complications such as LGD,HGD, andadeno-
carcinoma. This, however, requires confirmation in
randomized, placebo-controlled, double-blind clin-
ical trials.
Theoretically, fundoplication, if perfectly per-
formed, should have the greatest potential of inhi-
bition of not only reflux of the acid/pepsins compo-
nent of GER but also its duodeno-gastric mixture.7
Its adenocarcinoma preventive potential in patients
with BE still remains to be demonstrated. Our il-
lustration (Fig. 3) may help to outline the role
of equilibrium between aggressive factors within
duodeno-GER and protective factors within sali-
vary and esophageal secretions in maintaining the
integrity within the BE mucosa and prevention of
the development of esophageal AdCa.
If pharmacological or surgical therapy normal-
izes the quality and the quantity of duodeno-
gastroesophageal reflux andmucosal protective fac-
tors remain normal, LGD/HGD should not develop
(left upper panel); however, if mucosal protection
still remains low (left lower panel), L/HGD may
develop but could remain nonprogressive. If phar-
macological or surgical therapy diminishes but does
not normalize the quality and the quantity of DGER
and mucosal protection remains strong or normal,
L/GHD could still develop without progression to
AdCa (right upper panel); however, if mucosal pro-
tection also remains impaired (right lower panel),
L/HGDmay inevitably develop and exhibit progres-
sion to AdCa.
Conclusion
Esophageal preepithelial mucosal defense mecha-
nisms in patients with BE are significantly im-
paired, potentially predisposing metaplastic epithe-
lium to further injury, chronic inflammation, and
progression, through LGD and HGD, to esophageal
adenocarcinoma.
3. What is the effect of 5-HT4 agonists on
esophageal EGF secretion in patients with
GERD and BE?
Antonio Taddei, Paolo Bechi, Giancarlo Fres-
chi, Maria Novella Ringressi, Duccio Rossi
Degli’Innocenti, Francesca Castiglione, and Em-
manuella Masini
antonio.taddei@unifi.it
Serotonin (5-HT) was discovered in intestinal cells
by an Italian researcher, Vittorio Erspamer, in the
early 30s. Since then both agonists and antag-
onists drugs towards 5-HT receptors have been
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particularly used for gastrointestinal motility dis-
orders, such as constipation, irritable bowel syn-
drome, nausea, and vomiting.11,12 There are many
5-HT receptors subtypes and some of them play
a mitogenic role throughout their activation.13 So
far, there is no evidence concerning the role of
5-HT4 receptors in GERD and BE patients. It is well
known that EGF is very important in the regulation
of the tissue integrity and its receptors seem to play
a role in cell proliferation as well as in oncogenesis
of the gastrointestinal tract.14 Moreover, these re-
ceptors are present throughout all the intestine and
are significantly increased in GERD.15
Preliminary experience
This preliminary study includes 22 patients, divided
in to three groups: controls, GERD, and BE patients.
Esophageal samples were taken from each patient
and cells were isolated and studied in order to eval-
uate cell proliferation, Western blotting, and secre-
tion analysis.
5-HT4 receptor expression, although present in
all the patients, significantly increases from controls
to GERD patients and then to BE patients.
Our preliminary data show that proliferation,
evaluated by means of tritiated thymidine incor-
poration, significantly increases from basal levels
in each of the three studied groups after incuba-
tion with 5-HT. This effect is more evident after
cell preincubation with 5-HT agonists, such as Cis-
apride, a partial agonist for both 5-HT3 and 5-HT4
receptors, and CJ033466, which is a selective 5-HT4
receptor agonist. On the contrary, preincubation
with a selective HT4 antagonist reverses prolifera-
tive activity to basal levels.
EGF expression and secretion was also studied,
andourfindings show that EGFexpression increases
from controls to BE patients. These data are con-
firmedby the analysis of the secretion inbasal condi-
tions in the three groups. Incubation with Cisapride
or selectiveHT4 agonists significantly increases EGF
secretion, and the selective antagonist reduces it to
basal levels (Fig. 4). In addition to 5-HT4 receptors,
EGF has the same effect on proliferative activity
evaluated by means of thymidine incorporation in
the three groups. Preincubation with EGF signif-
icantly increases proliferative activity in the three
groups, on the contrary, preincubation with a se-
lective COX-2 inhibitor, such as Celecoxib, reduces
proliferative activity to basal level. Finally, our data
show that 5-HT agonists and, mostly, selective HT4
agonists increase PGE2 secretion. Conversely PGE2
is decreased by the selective 5-HT4 antagonist that,
therefore, determines the COX-2 activity increase.
In conclusion, in GERD and BE patients, 5-HT4
could play a role that involves both EGF and COX-
2 pathways, both determining PGE2 secretion in-
crease, and consequently proliferative activity in-
crease. Our preliminary data suggest that the 5-HT4
receptor involvement may be very important, at an
early stage of GERD multistep process, inducing
cell proliferation by means of EGF and/or COX-2
increased activity. Therefore, 5-HT4 selective antag-
onists could be the future of GERD therapy and
Figure 4. Incubation with cisapride or selective HT4 agonists significantly increases EGF secretion, and the selective antagonist
reduces it to basal levels.
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BE chemoprevention, but further both experimen-
tal and clinical studies in order to support this hy-
pothesis are needed.
4. What is the effect of lubiprostone on
chloride channel-2 (ClC-2) driven secretion
of protective components of mucus in the
human esophagus?
Marek Majewski, Grzegorz Wallner, and
Jerzy Sarosiek
Jerzy.sarosiek@ttuhsc.edu
The alimentary tract mucosa is covered by a visco-
elastic, approximately 200 micron thick, mucus–
buffer layer. The primary role for this layer is to
protect the delicate surface epithelium from var-
ious chemical and physical aggressive factors and
forces, either elaborated endogenously or from ex-
ogenous food components, providing also lubri-
cation facilitating propagation and propulsion of
nondigestible food solids. There is a close interrela-
tionship between the rate of mucus release from the
gastrointestinal mucous cells or from submucosal
mucous glands within the esophageal mucosa, and
the rate of chloride secretion, setting the optimal
conditions for hydration of mucus and formation
of its viscoelastic gel layer. Chloride channels type
2 (CIC-2) are widely distributed in tissues through
the body and are expressed in many epithelia, es-
pecially within the alimentary tract. Lubiprostone,
a member of a group of compounds called pros-
tones, within the family of prostanoids, is a locally
acting chloride CIC-2 channel activator that en-
hances a chloride-rich fluid secretion, subsequently
resulting in an increase of the alimentary tract se-
cretion, including mucus, driven by stimulation of
chloride sodium, thus accelerating transit and al-
leviating symptoms associated with chronic con-
stipation regardless its etiology. It has been clearly
demonstrated that the human esophageal mucosal
secretory response is closely related to its lumi-
nal exposure to acid and pepsin, thus setting the
stage for its role in esophageal mucosal protection
during gastroesophageal reflux. This secretory re-
sponse is augmented by serotonin receptor 5-HT4
agonist. Therefore, administration of lubiprostone
may result in increase of secretion of other protec-
tive factors within the mucus-buffer layer such as
prostaglandins, EGF, transforming growth factor 
(TGF-), thus enhancing the esophagel preepithe-
lial defence mechanisms. Hypothetically, by pro-
moting the quantity and the quality of the mu-
cus barrier along the alimentary tract, lubiprostone
could also be of value in mucosal protection during
administration of nonsteroidal–antiinflammatory
drugs (NSAIDs), well known for their ulcerogenic
potential both within the upper and the lower ali-
mentary tract, mediated by an impairment of COX-
1-generated prostaglandins and subsequent deple-
tion in mucus production, thus increasing the risk
of complications.
The integrity of the alimentary tract mucosa de-
pends upon equilibrium between aggressive factors
and defense mechanisms.16 Since aggressive factors
within the alimentary tract always act on the luminal
side of the mucosa, preepithelial defense, defined as
the mucus-buffers layer with its inherent pH gradi-
ent, represents the vanguard of mucosal defense.17
Mucin, also called mucus glycoprotein, generates
the architectural framework or scaffold within the
mucus layer supporting contribution of other pro-
tective components, including hydrophobic phos-
pholipids and buffers to its ultimate defensive
potential.16,17 Therefore, the rate of synthesis and
secretion of mucin is pivotal for the thickness of the
mucus-buffers layer and its ability to inhibit hydro-
gen ion back-diffusion andmaintain a pH gradient,
from acidic on its luminal perimeter to near neutral
at mucus–epithelial cell membrane inter phase.18
Administration of a conventionalNSAID, leading to
the development of peptic ulcer disease (PUD), or
inducing symptoms of nonulcer dyspepsia (NUD)
or chronic constipation, results both in decreased
generation of gastroprotective prostaglandins gen-
erated by COX-1 and diminished production of
gastric mucin.19
We have recently demonstrated, in a double-
blind, placebo-controlled study protocol where
administration conventional NSAID, naproxen,
500mg bid, resulted in a significant decline of
gastric mucus production by 44% (P < 0.001)
in basal conditions and by 35% (P < 0.001) in
pentagastrin-stimulated conditions, mimicking the
food-stimulated scenario.19 Furthermore, the rateof
secretion of gastric mucin, the major component of
mucus, during naproxen administration, declined
by 39% in basal conditions (P< 0.01) and by 49% in
pentagastrin-stimulated conditions (P < 0.005).19
Of note, administration of rabeprazole, one of
the most effective PPIs, resulted in significant
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restorative capacity on naproxen-induced decline
of mucus secretion bringing it rate of secretion al-
most to prenaproxen levels.19 This decline of mu-
cus andmucin production during administration of
naproxen may at least partly explain the propensity
of patients receiving NSAIDs for the development
of alimentary tract symptoms and complications.
An interrelationship exists in the esophageal mu-
cosa between secretion of mucin and other protec-
tivemucus components and chloride throughClC-2
within the alimentary tract.
It is hard to overestimate the value of adequate
chloride secretion into the alimentary tract lumen,
which is pivotal in regulating optimal rate of hydra-
tion of the luminal content, securing adequate fluid-
ity, andpromoting its adequate propulsion along the
alimentary tract.20,21 Furthermore, chloride secre-
tion is instrumental in secretion and hydration of
gastricmucus and its ability to form gel-like, viscous
physical property, instrumental in mucosal protec-
tion and lubrication. Recently, a novel agent, the
chloride channel activator lubiprostone, has been
introduced into our clinical armamentarium, tar-
geting an important pathogenetic link leading to
chronic constipation.20,21 The stimulatory impact
of lubiprostone on mucus and mucin production
and its viscous, gel-like forming property in asymp-
tomatic volunteers and patients with chronic con-
stipation has recently been explored (unpublished
data).
Future implications
The impact of chloride channel stimulators, espe-
cially from the family of prostanoids, as well as from
the group of prostones on secretion of protective
factors such as sodium bicarbonate, mucin, EGF,
and TGF- from salivary and esophageal submu-
cosal mucous glands in the health and disease of
the esophageal mucosa, especially in patients with
BE with and without LGD/HGD, remains to be
explored.
5. In view of the high levels of
toxin-producing Campylobacter species
found in Barrett’s patients, should
prophylactic use of antibiotics be
considered?
John F. Dillon and Katie Blackett
j.f.dillon@dundee.ac.uk
BE is a premalignant state leading to adenocarci-
noma of the esophagus, its close proximity to the
stomach raises the obvious question whether bac-
teria also play a role in disease progression in the
esophagus. The GI tract plays host to a large range
of bacteria, which helps the physiological process
of digestion, while boosting immunity to microbial
and other antigens from birth. The immune sys-
tem requires the presence of commensal bacteria
to facilitate its development and maintain its nat-
ural immunity to pathogenic microorganisms. The
microbiota, and its dysregulation, lead to chronic
inflammation, as seen in gastric cancer and pos-
sibly colon cancer. In the gastro intestinal tract,
these organisms play a major role in immune reg-
ulation, and therefore changes in bacterial com-
position in GERD due to cellular modifications
may initiate or maintain neoplastic progression to
esophageal carcinoma. So the first step to answering
the posed question iswhat bacteria are present in the
esophagus?
The esophagus can be infected with a number of
organisms, including Candida, Cryptococcus, my-
cobacteria, and herpes virus. However, studies by
Osias et al.,22 Pei et al.,23 andMcFarlane et al.24 have
demonstrated a biofilm in the esophagus. They have
identifiedmany species of bacteria belonging to dif-
ferent genera and phyla. Although the majority of
species are of an oral origin, the predominant oral
phyla, spirochaetes are not present, providing evi-
dence that not all oral bacteria can colonize these
tissues. Studies have been done on the bacterial col-
onization in patients with reflux esophagitis and
BE. Several groups of bacteria have been identi-
fied like Streptococci, Staphylococci, Gemella, Veil-
lonella, Neisseria, Prevotella, and Fusobacteria. Al-
though total colony forming units in healthy and
BE patients were similar, there is great species di-
versity.23–25 More recently, studies have shown the
continuation of this colonization of the esophagus
by campylobacter into those with esophageal car-
cinomas. The five bacterial phyla that are com-
monly identified in all patients at different stages
of the reflux–GERD–Barrett’s spectrum are: Firmi-
cutes,Actinobacteria, Proteobacteria, Bacteroidetes,
and Fusobacteria. The above studies did not re-
veal any specific organisms that were present in the
majority of disease phenotypes that did not occur
in any of the healthy controls. Nevertheless, dif-
ferences in the prevalence of particular bacterial
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groups, and relative bacterial numbers were ob-
served, with the microbiota becoming increas-
inglyGram-negative.Campylobactermanifested the
greatest increase during disease progression. The in-
creased presence of potentially pathogenic nitrate-
reducing Campylobacter species in disease patients
is of concern. The increased prevalence of nitrate-
reducing Campylobacter concisus, not only in BE
patients as found previously but also in those with
GERD and ADC, may increase the mutagenic po-
tential of refluxate.
This evidence confirms the presence of these
bacteria in association with disease progression,
and they have biological effects that could en-
hancemutagenesis ormitogenesis within the esoph-
agus, but, thus far, there is no evidence of causal-
ity. This provides justification for further research
but little evidence on which to base therapy upon.
Turning again to the question posed, we have to
ask if antibiotics are the correct therapy to con-
sider, if we did want to eradicate campylobacter
from the esophagus. The paradigm proposed is
based directly on experience of Helicobacter pylori
eradication in the stomach, where there is a very se-
lective niche for colonization and an acid barrier to
prevent recolonization. The same conditions do not
apply in the esophagus where there is a very diverse
microbiota and a ready reservoir of bacterial recol-
onization from the mouth. This would require con-
tinuous use of antibiotics with the attendant prob-
lems of resistance and secondary infections.
Therefore, the current knowledge about the mi-
crobiota of the esophagus, and in particular it’s col-
onization with Campylobacter species, does not jus-
tify eradication with antibiotics.
6. What is the link between presence of
unconjugated bile acids and the
deleterious effect of refluxate in patients
taking PPIs?
Katerina Dvorak and Aaron Goldman
kdvorak@email.arizona.edu
In BE, normal esophageal mucosa is replaced by
columnar epithelium resembling intestinal tissue.
This lesion of distal esophagus is associated with
chronic GERD and predisposes patients to develop
esophageal adenocarcinoma (EAC). However, the
precise mechanism of development of BE and EAC
is unclear. The incidence of EAC has been rapidly
increasing in the last three decades and, interest-
ingly, this increase correlates with the introduction
of PPIs on market.
Epidemiological, animal, and clinical studies sug-
gest that BE is formed in response to stress induced
by two major components of refluxate: gastric acid
and bile acids. Bile acids in combination with acid
inducenitrosative stress, oxidative stress,DNAdam-
age, and alterations in cell signaling. Furthermore,
bile acids may induce the expression of proteins as-
sociated with phenotypic switch from normal squa-
mous to intestinal phenotype such as Klf-4, villin,
and CDX2.
PPIs, since their discovery in the late 1980s, have
been largely used for treatment of acid related disor-
ders, including BE. PPIs decrease secretion of gastric
acid by inhibiting H+/K+ ATPase of parietal cells
and alleviate symptoms associated with acid reflux.
However, it is not clear if this therapy can completely
suppress reflux of duodenal contents. Clinical stud-
ies using the Bilitec 2000 R© probe demonstrated that
bile reflux is more common, and concentrations of
bile acids are significantly higher in patients with BE
than in patients with GERD. Furthermore, during
the last five years, concerns have been raised, since
long-term treatmentwithPPIsmayproduce adverse
effects. In this review, we summarize the effects of
PPIs on bile acids.
No treatment (pH∼2)
• Unconjugated and glycine-conjugated acids
irreversibly precipate at normal stomach pH
• Taurine conjugated bile acids are soluble but
they constitute only ∼20% of total bile acids
• Nobacterial overgrowth; no formation or sec-
ondary bile acids
• Bile acids are less concentrated
• Normal gastric emptying
• Normal gastrin levels
PPI (pH>4)
• Unconjugated and glycine-conjugated acids
are soluble; they can interact with esophageal
mucosa
• PPIs decrease overall stomach secretion and
thus bile acids present in the stomach aremore
concentrated
• Bacterial overgrowth; bacteria induce forma-
tion of more toxic unconjugated bile acid
• Delayed gastric emptying
• Hypergasterinemia
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Bile acids present in bile are conjugated with
glycine or taurine, however there is small fraction of
unconjugated bile acids in the normal bile. Glycine-
conjugated bile acids represent more than 70% of
all bile acid pool while taurine conjugated bile acids
represent about 20%. Unconjugated bile acids are
known to bemore toxic compared to bile acids con-
jugated with glycine or taurine.
First, the stomach is normally free of bacteria,
with the exception ofH . pylori. PPI treatment is as-
sociated with bacterial overgrowth in the upper gas-
trointestinal tract, since the increase in pH creates
environmentmore permissive for bacterial prolifer-
ation.26,27 Amajority of bacterial species residing in
the stomach and duodenummay induce the decon-
jugation and dehydroxylation of primary bile acids
to form more toxic, unconjugated, secondary bile
acids, such as deoxycholic acid.26,27 Indeed, stud-
ies show bacterial overgrowth and elevated levels of
unconjugated bile acids in the gastric juice of pa-
tients treated with PPI.28 The recent study of Yang
et al. indicates that intestinal metaplasia of the distal
esophagus is associated with alterations in the mi-
crobiome (a shift fromaGram-positivemicrobiome
in normal esophagus to that of a Gram-negative
anaerobic microbiome in inflamed/BE), however it
is not clear from this study if patients were treated
with PPIs.28
Second, the majority of bile acids (glycine con-
jugated and unconjugated) irreversibly precipitate
at normal acidic environment of stomach (pH∼2),
thus they cannot cause cell damage or the alter-
ations in cell signaling. In contrast, at higher pH
(i.e., pH > 4) glycine conjugated bile acids are sol-
uble, unionized, and thus active since their pKa is
about 4. Glycine conjugated bile acids are the most
prevalent bile acids in human bile and thus increase
of stomach pH by PPIs treatment to pH > 4 may
lead to the cellular damage by bile acids. Uncon-
jugated bile acid have pKa ∼6.2, and thus they are
are most active at this pH. In our studies, we have
previously shown that acid, in combination with a
bile acid cocktail that reflects the composition of
bile acids present in the refluxate, induces oxidative
DNA damage in vitro in different cell lines and ex
vivo in esophageal biopsies.29
Third, since secretion of gastric acid in the stom-
ach is reduced, then volume of secreted gastric juice
is also low. Thus, concentration of bile acids refluxed
into stomach and, consequently, to esophagus, is
higher compared to the normal stomach where the
secretion of gastric juices is high.
Fourth, PPIs may cause hypergastrinemia. In-
creased gastrin is linked to proliferation and cancer
development.30 Finally, PPIs have been shown to
induce delayed gastric emptying, which may com-
promise the LES and increase the reflux of bile in
the esophagus.
In summary, acid suppression therapy with PPIs
may lead to the bacterial overgrowth and increased
reflux of toxic, unconjugated bile acids. This may
result in increased cell DNA damage, mutations,
and, consequently, to BE and EAC development.
7. Should baclofen be added to PPIs to
address nonacid and bile reflux factors?
Philip Woodland and Daniel Sifrim
d.sifrim@qmul.ac.uk
GERD, which is refractory to PPI therapy, is a fre-
quently encountered clinical problem. This situa-
tion is most commonly, although not exclusively,
found in patients with nonerosive reflux disease
(NERD) in whom the response rate may be as
low as 45%. In some cases of PPI refractoriness,
the mechanism may be insufficient acid suppres-
sion by the PPI. This may be due to patient fac-
tors such as poor compliance or improper dosage
time (i.e., not taken 30 min before mealtimes), or
phamacokinetic/pharmacodynamic factors such as
reduced PPI bioavailability, rapid PPI metabolism,
or biological resistance to PPIs. These reasons may
be best addressed by patient education, rational-
ization of medication regimes, and use of alterna-
tive acid-suppressant agents. However, a proportion
of GERD patients have continued reflux-associated
symptoms despite adequate efficacy of PPI therapy.
These patients often have physiological esophageal
acid exposure, yet when testedwith 24-hmultichan-
nel intraluminal impedance (MII) studies, they have
symptoms associated with reflux events that are not
acidic, i.e., they may have sensitivity to reflux of
other types. The refluxate in these cases may be
weakly acidic (pH > 4), and may contain bile com-
ponents from DGER, or even gas.
Weakly acidic reflux as a cause of GERD
symptoms
A study of 60 symptomatic GERD patients taking,
and refractory to, PPI revealed that weakly acid
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Figure 5. Transient lower esophageal sphincter relaxations can be responsible for acid, weakly acidic, and bile reflux events.
reflux was responsible for persisting regurgitation
in 35%, cough in 20%, and heartburn in 7% of
cases. Weakly acidic reflux appears to be of particu-
lar importance inNERDpatients. Emerenziani et al.
showed that 24% of GERD symptoms in NERD pa-
tients were attributed to weakly acidic reflux. There
has been recent interest in the role of gaseous re-
flux symptom generation in GERD. Within their
pH-MII study in GERD patients, Emerenziani et al.
investigated the relationship between gaseous re-
flux (as measured by MII) and symptoms. They
showed that in patients with NERD, the presence
of gas with the liquid refluxate was associated with
an increased probability of symptom perception. A
similar study using pH-MII demonstrated that pa-
tients with NERD had an increase in gas-containing
reflux episodes compared to controls. DGER is be-
lieved to be important in the genesis of a propor-
tion of continuing symptoms despite PPI therapy,
although the extent of its role remains controver-
sial. Initial studies by the Leuven group suggested a
significant role for DGER in PPI-refractory GERD.
When patients with persistent reflux symptoms,
despite therapy, were studied PPI, DGER (mea-
sured by esophageal bilirubin spectrophotometry)
was found to be rather important, being related to
18% of symptomatic episodes versus 7% for acid
and 10% for mixed reflux. Conversely, other studies
have suggested a less important role for DGER in
PPI-refractory GERD. Gasiorowska et al. studied a
similar group of patients, and found DGER alone
to be of a relatively lesser relevance, being related to
9%of symptom events versus 32% for acid and 32%
for mixed reflux. Moreover, the amount of DGER
in PPI-refractory patients was similar to that in
PPI-responsive patients.
The TLESR as a therapeutic target
If weak acid, DGER, and gas can be responsible for
GERD symptoms, it is perhaps not surprising that
a proportion of patients remain refractory to PPI
therapy. Although PPIs have been shown to reduce
both acid and DGER, it would follow that for some
patients an alternative therapeutic target to the pro-
ton pump should be addressed. The common factor
associated with any reflux, be it acid, weak acid,
DGER or gas, is the TLESR (Fig. 5). TLESRs are
triggered in response to activation of stretch recep-
tors in the stomach and are thought to be mediated
by a vago-vagal reflexpathway.Gastroesophageal re-
flux almost always occurs in the context of a TLESR,
and so the suppression of these relaxations is an
attractive therapeutic target. This was first shown
to be plausible by Mittal et al. in 1995 when at-
ropine was shown to reduce both TLESR frequency
and the number of reflux events in normal sub-
jects.31 Subsequently, GABAB agonists (an example
ofwhich is baclofen) have also been shown to reduce
the rate of postprandial TLESRs and reflux episodes
in humans. GABAB receptors act at several points
along the vagal mechanoreceptor signaling path-
way. Vela et al. studied nine healthy volunteers and
nine symptomatic reflux patients with esophageal
pH-impedance after both placebo and a single dose
of baclofen. Baclofen was found to cause a signifi-
cant reduction in both acid and nonacid reflux in
all subjects.32 The potential benefits of baclofen on
DGERhave also been shown.Koek et al. investigated
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patients with PPI-refractory GERD who showed
normal esophageal acid exposure, but who had
pathological DGER on Bilitec monitoring. The ad-
dition of baclofen 20 mg three times daily to high-
dose PPI therapy significantly reduced the num-
ber of DGER episodes, esophageal duodenal re-
flux exposure, and symptoms.33 A further placebo-
controlled study of 16 patients showed that 10mg
baclofen four times daily significantly reduced re-
flux events and improved symptoms.34 Although
effective at inhibiting TLESRs, the clinical use of
baclofen is limited by its side-effect profile, caus-
ing troublesome symptoms such as dizziness and
nausea. Recently, attention has turned towards
new GABAB-receptor agonists that act primarily
at peripheral sites and, therefore, have better tol-
erability. The newly developed, peripherally act-
ing GABAB-receptor agonist lesogaberan has been
shown to have a favorable safety and tolerabil-
ity profile. Furthermore, in a randomized, double-
blind, placebo-controlled trial in patients with PPI-
refractory symptoms, lesogaberan significantly re-
duced TLESR frequency and number of reflux
episodes compared to placebo.35
Summary
PPI-refractory GERD is a commonly encountered
clinical problem. Before considering add-on ther-
apy, reversible reasons for PPI failure (e.g., patient
compliance) should first be sought. However, a sub-
groupof patients canbe identified inwhomongoing
symptoms are related to reflux events that are not
acidic. In this group of patients the reduction of
TLESR frequency is a potentially beneficial thera-
peutic strategy. GABAB-receptor agonists have been
shown to be effective in reducing acidic and weakly
acidic reflux events, and can reduceDGER. Baclofen
is a reasonable therapeutic add-on in those with
persistent symptoms due to nonacid reflux in those
who can tolerate it. The development of newer drugs
withmore favorable side-effect profiles is encourag-
ing progress for the management of this difficult-
to-treat group of patients. The search for the ideal
TLESR-inhibiting drug remains ongoing.
8. In patients on PPI therapy, what is the
threshold for adequate suppression of




The normal esophageal pH values for healthy vol-
unteers are well defined.However,many patients we
study today are taking PPIs, and the degree of ap-
propriate acid control on antacid medications has
clinical relevance. Unfortunately, the threshold for
adequate esophageal acid control on PPI therapy is
poorly studied.
The single, widely quoted study addressing this
question is from Brad Kuo,MD andDonald Castell,
MD at Graduate Hospital, Philadelphia.36 They
studied 19 healthy male volunteers (mean age 25
years) assessing both esophageal and gastric pH in
a randomized singled blinded protocol with three
dosing arms: 40 mg omeprazole in the morning be-
fore breakfast, 40 mg omeprazole in the evening
before dinner, and 20 mg twice a day before break-
fast and dinner. Before each session, a baseline am-
bulatory pH study on each patient was done. Each
Figure 6. Dosing regimens caused a significant reduction (P < 0.01) in distal esophageal acid exposure compared with baseline.
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session was carried out over at least five weeks with
each dose session separated by at least a one-week
washout period. Subjects received seven days of each
dosing regimen followed by pH testing.
As shown inFigure 6, all dosing regimens caused a
significant reduction (P < 0.01) in distal esophageal
acid exposure compared with baseline. However,
there was no significant difference among these dos-
ing regimens with the range of means very tight at
1.0% to 1.1% for the total acid exposure time. The
95% confidence interval for the upper limit of acid
exposure in these 19 volunteers across all studieswas
1.6% on omeprazole 40 mg.
Using this threshold value of 1.6%, the same
group performed a retrospective analysis of 45 pa-
tients with persistent GERD symptoms on omepra-
zole 20 mg BID.37 Of this group, 14 (31%) had re-
flux that was poorly controlled based on the new
threshold value of 1.6%. However, this separation
did not characterize patients who would respond
to increasing the omeprazole dose to 20 mg QID.
Of the five patients with typical GER symptoms
and pH >1.6%, three responded to the higher
omeprazole dose. All three of the responders had
a good symptom response on pH testing. In the
ten patients (one overlapped with heartburn) with
primarily atypical symptoms and pH >1.6%, only
one patient with a good symptom correlation im-
proved with QID omeprazole treatment. Thus, only
4 of 11 (36%) patients (three lost to treatment
follow up in the atypical group) with pH thresh-
olds>1.6% and persisted symptoms improvedwith
higher doses of PPIs.
This data gives us little confidence in theproposed
pH threshold <1.6% on PPI therapy and suggest
that larger studies and possibly a multicenter study
is required to appropriately address this issue. Until
this time, our and most other groups, define ade-
quate acid control in GERD patients as values below
normal thresholds for healthy controls, usually %
total acid exposure time of less than 4.5–5.5%.
9. What are the effects of PPIs on
stabilization of basal cell proliferation,
reduction of cell cycle abnormalities, and
hyperplasia of the basal cell layer?
Michael Vieth, Helmut Neumann, and
Cord Langner
Vieth.LKPathol@uni-bayreuth.de
The effects of PPIs on esophagealmucosa are depen-
dent on the type of epithelium present. Physiologi-
cally, the esophagus is covered by squamous epithe-
lium. When the squamous epithelium is replaced
by columnar epithelium (BE), effects on columnar
epithelium can be observed as well.
Squamous epithelium
The esophagus is physiologically lined by nonkera-
tinized squamous epithelium. Proliferation (regen-
eration) starts from the basal cell layer. Stromal
papillae that extend into the epitheliummainly con-
tain small capillaries. In reflux disease, increased
proliferation leads to thickening of the basal cell
layer and elongation of stromal papillae (Fig. 7).
Capillaries are now located closer to the mucosal
surface, and this corresponds to increased redness
of themucosa during endoscopy. At highmagnifica-
tion endoscopy dilated capillary loops may be seen.
The thickness of the basal cell layer and the length
of the papillae can be expressed as percentages in
relation to the thickness of the entire squamous ep-
ithelium. A relationship between these percentages
and the severity of disease may be noted: the more
severe the reflux disease (according to the Los Ange-
les classification), the more pronounced the thick-
ness of the basal cell layer and the length of the
papillae. After PPI therapy these values drop down
markedly. Even if missing or poor controls do not
allow aprecise definitionofwhat is normal andwhat
is already abnormal, it may be speculated that nor-
mal values are very close by to these values induced
by PPI therapy (Fig. 8). Since under PPI the length
of papillae decreases, capillaries move further away
Figure 7. Histology of esophageal squamous epithelium in
an individual without pathological changes (left) and an indi-
vidual with endoscopy negative reflux disease (NERD) (right).
Proliferating cells are marked immunohistochemically by Ki67.
Circle = basal cell layer; brackets = length of stromal papilla;
distance holder= epithelial thickness.
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from the lumen leading to a decreased redness of
the mucosa up until virtual normalization during
endoscopy.38
Columnar epithelium
Columnar metaplasia of the distal esophagus (BE)
is regarded as a precancerous condition. The risk
for malignant transformation is up to 125 times
higher than in the normal population. Cancer risk
can also be expressed as 0.5% per year for individu-
als with BE. How to decrease this risk? One option
is to remove the esophagus or at least part of it by
surgery. This approach would be linked to numer-
ous procedure-related side effects. The question is
whether PPI therapy is capable of lowering the risk
of malignant transformation, since PPI therapy is
known to decrease proliferation, enhance differenti-
ation, andpromote epithelialmaturation.Notmany
publications are available on this topic and the study
design of the few reports available is limited. It ap-
pears, however, that PPI therapy reduces the risk of
malignant transformation.39–42 NSAIDsare thought
to cause a trend only, but no significant reduction
on its own. Of note, several reports stressed that the
effects of PPI therapymaybe related todifferent pro-
files in acid exposure. Namely there are differences
in continuous versus pulse acid exposure. The ep-
ithelium of patients with continuous acid exposure
is believed to only partially benefit from PPI ther-
apy, whereas the epithelium of patients with pulse
acid exposure, leading to more pronounced epithe-
lial changes, might have a greater potential to be
positively influenced/cured by PPI therapy.
It needs to be stressed that these data, although
corresponding nicely with our expectations, are so
far only limited, based upon few (observational)
studies with few tested individuals, sometimes bi-
ased by poor study design (such as decreased bile re-
flux under PPI-therapy), or even nonreproducible.
Thus, although the mechanisms have not yet been
fully understood, at least a trend to risk reduction
during PPI-therapy is accepted in the literature.
Length regression of BE has been known for a
long time,43 but to be significant it should exceed
10% of the area covered by columnar epithelium.
Especially in short segments this cannot properly be
accessed by endoscopy since, for example, 10% of
3 cm would sum up as only 3 mm in length reduc-
tion. Again only a trend has been documented so
far even if Barrett’s will not disappear completely in
most cases.
In conclusion, established PPI effects on squa-
mous epithelium are:
1. increase of squamous islands;
2. reduction of cell proliferation;
3. improvement of differentiation;
4. reduction of acid reflux;
Figure 8. Changes in esophageal squamous epithelium after PPI therapy focusing on length of stromal papillae and thickness of
basal cell layer related to severeness of reflux disease assessed by Los Angeles classification (LA Grade). Modified after Vieth et al. 38
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5. ERD healing improves detection of neoplasia;
6. adjuvant treatment to ablation therapy; and
7. symptom control.
PPI effects on columnar epithelium are partially
based on much weaker evidence:
1. regression of Barrett’s length (10% !);
2. reduction of cell proliferation (?);
3. improvement of differentiation (?);
4. decreased COX-2/VEGF expression and PGE2
release;
5. reduction of bile reflux (?);
6. ERD healing improves detection of neoplasia;
7. adjuvant treatment to ablation therapy; and
8. symptom control.
10. Can PPI therapy achieve normalization
of esophageal pH in Barrett’s patients?
George Triadafilopoulos
vagt@stanford.edu
The use of PPIs is almost universal in patients with
BE.Thesedrugs effectively control reflux symptoms;
heal mucosal damage; prevent recurrent esophagitis
and/or stricture formation; partly regress the meta-
plastic surface; induce formation of neosquamous
islands; reduceDEGR,minimizing the impactof bile
on the metaplastic epithelium; facilitate the recog-
nition and regression of dysplasia; and may pre-
vent dysplasia and adenocarcinoma by decreasing
cell proliferation, exerting potentially a chomopre-
vention effect. In this context,maximumesophageal
pH control (esophageal pH normalization) is gen-
erally considered as essential. PPI therapy is also an
important adjuvant treatment to ablation modali-
ties, facilitating neoepitheliazation.44
Figure 9A shows an example of “ideal” pH con-
trol in BE, where the esophageal pHwas normalized
to pH< 4.0 for less than 4% using esomeprazole 40
mg bid, and partial suppression of intragastric acid-
ity was accomplished. In contrast, Figure 9B shows
“poor” pH control in BE where the esophageal pH
remained persistently abnormal despite esomepra-
zole 40 bid; partial and inadequate suppression of
intragastric acidity, particularly at night was noted.
In one study, 62% of patients failed to achieve
complete esophageal acid suppression (24-h pH
< 4.0 for > 5% time) despite esomeprazole 40 mg
bid; typically esophageal pH reflects gastric pH, par-
ticularly at night (supine position).45 In another
“dose response” study with esomeprazole, 31 pa-
tients with BE were noted to accomplish gastric
pH >4.0 for 88.4%, 81.4%, and 80.4% of day 5
Figure 9. (A) “Ideal” pH control in Barrett’s esophagus: esophageal pH is normalized to pH <4.0 for less than 4%; partial
suppression of intragastric acidity. (B) “Poor” pH control in Barrett’s esophagus. Esophageal pH is persistently abnormal despite
esomeprazole 40 bid; partial and inadequate suppression of intragastric acidity (originally published in Ref. 45).
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after treatment with esomeprazole 40 mg tid, 40 mg
bid, and 20 mg tid, respectively. The esophageal pH
remained abnormal in 16%, 23%, and 19% of pa-
tients receiving esomeprazole 40 mg tid, 40 mg bid,
and 20 mg tid, respectively.46
In a crossover trial, there were no significant dif-
ferences among three PPIs (lansoprazole, omepra-
zole, and esomeprazole) in controlling esophageal
pH. Although all these patients had no GER
symptoms, many exhibited persistently abnormal
esophageal pH.47 There are no predictors of nor-
malization of esophageal acid exposure in BE pa-
tients. In a cohort study of 46 patients with BE, 25%
continued to have abnormal esophageal pH profiles
despite bidPPI, and age, BE length, andhiatal hernia
size did not predict the persistence of abnormal in-
traesophageal pH.48 It appears that acid remains in
the esophagus of Barrett’s patients because of poor
peristalsis of the esophageal body, and most of the
reduction in esophageal pH exposure with PPI hap-
pens in the upright, not supine position. Similarly,
upright—not supine—duodeno-gastro-esophageal
(bile) refluxwas significantly reduced by PPI in such
patients.49
In conclusion, a high percentage of patients with
BE continue to exhibit pathologic GERD and low
gastric pH despite high (bid-tid) doses of PPI and
all PPIs have a similar effect. For an antisecretory
treatment aimed at chemoprevention to be effective,
higher PPI dosing, confirmed by pH monitoring, is
necessary.
11. Are different effects of PPI therapy to
be expected in relation to the predominant
phenotype of cellular proliferation in
Barrett’s epithelium?
Norihisa Ishimura and Yuji Amano
amano@med.shimane-u.ac.jp
The chemopreventive effect of PPIs for BE has been
extensively studied; however, its role remains un-
clear. Epidemiologic studies suggest a protective ef-
fect of PPIs against neoplastic changes and progres-
sion in BE; however, the data are contradictory. It is
well known that BE consists of two secreted mucin
phenotypes, namely gastric and intestinal. The pre-
dominant mucin phenotype has been reported to
have a more malignant potential. Consistently, we
have shown that Barrett’s epithelium with intestinal
predominant mucin phenotype showed markedly
elevated cellular proliferation and suppressed apop-
tosis, as compared to that with gastric predominant
mucin phenotype.50,51 Therefore, the controversy
regarding the chemopreventive potential of PPI, in-
cluding the suppression of COX-2 expression and
cell proliferation, and the induction of apoptosis,
may be the diversity of the mucin phenotype of
Barrett’s mucosa. The aim of this study52 was to
evaluate the effect of PPIs on cellular proliferation,
COX-2 expression, and apoptosis in BE with differ-
ent mucin phenotypes.
Materials and methods
Four hundred and nineteen consecutive patients
with histologically proven BE were enrolled in the
study.52 Patients were divided into two groups,
nontreatment patients (n = 358), and chronic
PPI users (n = 61), which were defined when
they were continuously administrated from at least
two months before endoscopy. Four hundred and
sixty-six biopsy samples of BE from 358 non-
treatment patients and 81 from 61 chronic PPI
users were immunohistochemically examined using
anti-COX-2 protein, antiproliferating cell nuclear
antigen (PCNA), and antisingle strand DNA (ss-
DNA) antigens in both mucin phenotypes of BE.
Results
Among nontreatment patients and PPI users, there
was no significant difference between the gastric and
intestinal predominant mucin phenotype.52 Preva-
lence of the COX-2 expression pattern did not sig-
nificantly differ between the nontreatment and PPI
users. In those using PPIs, significant suppression of
cellular proliferation assessed by PCNA was found
in BE with the gastric predominant mucin pheno-
type, but notwith the intestinal predominantmucin
phenotype. Apoptosis indices assessed by ssDNA in
chronic PPI users did not significantly differ be-
tween the two mucin phenotypes.52
Discussion
Acid exposure is considered themain factor not only
in thedevelopmentofBE,but also in the carcinogen-
esis of Barrett’s adenocarcinoma. In this study, we
have demonstrated that PPIs showed an inhibitory
effect oncellularproliferationonly in thegastricpre-
dominantmucin phenotype but not in the intestinal
predominant mucin phenotype showing more ac-
celerated cellular proliferation activity (Fig. 10).52
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Figure 10. The effect of PPI on cell proliferation in BE.
In BE with the intestinal-predominant mucin
phenotype, COX-2 expression and subsequent pos-
sible overproduction of prostaglandins is closely
related with the acceleration of cellular prolifera-
tion and the inhibition of apoptosis. However, the
suppressive effect of PPIs for COX-2 expression in
BE was not found in this study.
Conclusion
PPIs suppress cellular proliferation in BE with the
gastric-predominant mucin phenotype but not in
that with the gastric-predominant mucin pheno-
type. This finding may at least partly explain the
ongoing controversy surrounding the notion that all
cases of BE respond to acid-suppressive therapy.
12. What are the respective values of the
Symptom Index, the Symptom Sensitivity
Index, and the Symptom Association
Probability for the interpretation of
causality of symptoms, and the potential
response to medical treatment?
Joel E. Richter
jrichter@temple.edu
The first symptom indices to relate acid reflux by
ambulatory pH testing with patients symptoms
evolved in the late 1980s.53 The “symptom in-
dex” (SI) is defined as the percentage of symptom
episodes that are related to reflux:
Number of reflux related symptom episodes/
Total number of symptom episodes × 100%.
The distribution of SIs in a population of patients
with heartburn appears to be bimodal, and the re-
sult of receiver operating characteristic analysis in-
dicates that the optimal threshold for SI is 50%. The
major shortcoming of the SI is that this index does
not factor in the total number of reflux episodes,
hence the higher the frequency of acid reflux, the
greater the likelihood that a symptom is associated
by chance. For this reason the “symptom sensitivity
index” (SSI) was proposed as an additional param-
eter. SSI is defined as:
Number of symptom associated reflux episodes/
Total number of reflux episodes × 100%.
SSI values of 10% or higher are considered to be
positive.53 It should be noted that these determined
thresholds have only been validated for heartburn
and regurgitation—not for chest pain or extrae-
sophageal symptoms. Furthermore, these indices
have not been validated for nonacid episodes. Both
the SI and SSI suffer from the disadvantage that they
do not integrate all factors determining the relation-
ship between symptoms and reflux. The “symptom
association probability” (SAP) is calculated by di-
viding 24-h pH data into consecutive two minute
windows.54 For eachof these twominutewindows, it
is determined whether reflux occurred and whether
symptoms occurred, giving a 2 × 2 contingency ta-
ble of S+R+, S–R+, S+R–, S–R–, respectively. Fish-
ers’ exact test is used to calculate the probability (p)
that theobserveddistribution couldoccurby chance
alone. SAP is calculated as (1 – p)× 100%; by statis-
tical convention, SAP≥ 95% is positive. Limitations
of validation outside classical GERD symptoms also
apply to the SAP.
Despite the availability of these symptom in-
dices, there is surprisingly little literature assessing
their predictive accuracy in a clinical population.
To perform this appropriately, a large patient pop-
ulation needs testing with outcomes followed after
aggressive PPI therapy or antireflux surgery. The
only study to date taking this approach was per-
formed by Taghavi et al. from Iran.55 The authors
studied 52 patients with a predominant symptom
of heartburn with baseline symptom scores calcu-
lated at the first visit. After 24-h pH testing off all
PPIs, the symptom reflux indices were calculated.
All patients were placed on high dose omeprazole
(40 mg AM, 20 mg at night) and symptom scores
recorded again oneweek later. A reduction of>50%
in the heartburn score was considered a positive
omeprazole test. Overall, the omeprazole test was
positive in 23 patients (52%). The concordance of
the three symptom indices and the omeprazole test
Ann. N.Y. Acad. Sci. 1232 (2011) 93–113 c© 2011 New York Academy of Sciences. 109
Barrett’s esophagus: proton pump inhibitors and chemoprevention Triadafilopoulos et al.
Figure 11. Concordance of the three symptom indices and the
omeprazole test.
is shown in Figure 11. All these indices were signif-
icantly related to each other (P < 0.001). However,
only the SAP and SSI had a statistically significant
relationship with the omeprazole test (P < 0.05 for
both). SSI had the highest positive (80.9%) and
negative (57.9%) predictive values and sensitivity
(73.9%). The specificity of the SSI and SAP (73.3%
for both) was lower than the SI (80%). These au-
thors could find no cutoff point at which the results
of SI could be related significantly to the omeprazole
test results. The authors concluded, “these symptom
reflux indices are unable to predict the response of
the one most typical symptom of GERD (heart-
burn) to the one most effective medical treatments
available.”55
No other studies have been reported to date to
address this issue in individual patients. However,
other studies have shown favorable trend data for
both the SAP and SI when assessing the response
for heartburn and regurgitation to PPI therapy over
several weeks.56,57 In these studies, those with a pos-
itive symptom index and abnormal reflux values
performed as a group best, followed by a positive
symptom correlation even with a normal pH test,
while not surprisingly those with both tests neg-
ative did the worst. Based on these limited data,
great caution is urged when using these test results
to predict a response to PPIs in individual patients,
especially those without classic heartburn or regur-
gitation. Large, possibly multicenter studies need to
be performed using strong clinical endpoints such
as symptom resolution to prolonged high dose PPI
therapy (BID dose for four to eight weeks) or antire-
flux therapy. Additional studies are also required to
validate the use of these indices with nonacid reflux
measured by impedance technology.
13. Can correlation between use of PPI and
development of dysplasia be considered?
Valter Nilton Felix
v.felix@terra.com.br
Use of PPIs may be useful to avoid the develop-
ment of dysplasia if there are not concomitant duo-
denogastroesophageal reflux (DGER) andother sys-
temic factors interacting, and if it could really nor-
malize esophageal acid exposure.
Reflux symptoms can be controlled in most pa-
tients with PPI therapy. Twice a day dosing may be
necessary in a subgroup of patients. However there
are currently no data that directly support the use
of high dose antisecretory therapy to delay or pre-
vent the development ofBarrett’s esophagus orEAC.
Even on higher doses of omeprazole of 40 mg bid,
as many as 24% of Barrett’s patients were shown to
have abnormal total or supine distal esophageal acid
exposure values. Limited prospective studies have
demonstrated normalization of esophageal pHwith
q.d. PPI therapy in over 90% of patients with typ-
ical reflux symptoms. On the other hand, patients
withmore severe degrees of erosive esophagitis have
significantly greater abnormal esophageal acid ex-
posure in spite of PPI therapy.58
Furthermore, adequate acid suppression may
mask the detection of nonacid reflux events. PPIs,
although effective in controlling the acid compo-
nent of the refluxate, do not eliminate the reflux of
bile, which some believe to be a major contributor
to the pathogenesis of Barrett’s epithelium. DGER
occurs in more than 50% of patients with erosive
esophagitis and BE,59 and the majority of bile re-
flux events occurred concomitantly with acid re-
flux. Tack et al.60 have recently published a series of
studies suggesting a possible role for DGER in both
symptoms and esophagitis in a subset of patients
with difficult to manage, symptomatic reflux. Sur-
prisingly, 51% of patients had erosive esophagitis
on endoscopy despite the fact that they were on PPI
therapy at the time of the study.60
Chronic inflammation seems to have a central
role in the development of esophageal adenocarci-
noma and its precursor lesions. The refluxate con-
tains numerous substances in addition to gastric
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acid, including bile salts, pancreatic enzymes, and
ingested foods and their metabolites, which can
cause acute and chronic inflammation of the
oesophageal epithelium with resulting oxidative
stress.
Abdominal obesity, in addition to promoting gas-
troesophageal reflux, is also increasingly being rec-
ognized as causing a state of low-level systemic
inflammation, characterized by increased plasma
levels of proinflammatory cytokines and receptors,
such as interleukin-6 (IL-6), TNF- and TNF- re-
ceptor 2, C-reactive protein and leptin.
In addition, cigarette smoking can cause inflam-
mation both systemically and in the esophageal
epithelium in response to swallowed smoking prod-
ucts. In turn, a chronic state of systemic and lo-
calized inflammation and oxidative stress promotes
DNA damage, cellular proliferation and telomere
shortening, which can increase the risk of devel-
oping clones containing small- and large-scale ge-
nomic alterations, eventually leading to widespread
chromosomal instability and esophageal adenocar-
cinoma.
The advisability of prescribing aggressive antire-
flux therapy for all patients with BE, irrespective
of the severity of their underlying GERD, has been
debated. One recent study has shown a decrease in
development of dysplasia in patients treated with
or prescribed PPIs.61 In multivariate analysis, the
use of PPI after BE diagnosis was independently
associated with reduced risk of dysplasia, hazards
ratio: 0.25 (95% CI 0.13–0.47), P < 0.0001. In this
same route, a retrospective observational study of
344 patients with BE, PPI treatment after diagnosis
of BE was associated with a reduced risk of HGD or
cancer.62
On the other hand, several uncontrolled, obser-
vational studies have found fewer cases of dyspla-
sia and cancer among patients with BE who had
antireflux surgery than among those who had re-
ceived medical treatment, and some even have pro-
posed that antisecretory therapy might predispose
to malignancy. However, the limited studies that
have addressed this issue directly have not found
a significant association between esophageal ade-
nocarcinoma and the use of antisecretory agents
per se.
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